Guanxinning tablets significantly reduced cardiac hypertrophy, inhibited myocardial remodeling and fibrosis, and improved cardiac function in rats with early heart failure by inhibiting the MEK-ERK1/2 signaling pathway.
Does Guanxinning tablet (GXN) reduce myocardial hypertrophy and improve early heart failure in a rat model?
Guanxinning tablets attenuate cardiac hypertrophy and improve early heart failure in a rat model, likely by inhibiting the MEK-ERK1/2 signaling pathway.
p-value: p=<0.05
Myocardial hypertrophy may lead to heart failure and sudden death. As traditional Chinese medicine, Guanxinning tablets (GXN) have significant pharmacological effects in the prevention and treatment of cardiovascular diseases. However, the anti-cardiac hypertrophy efficacy of GXN and its mechanism of action are still unclear. Therefore, we established a heart failure rat model and isolated primary cardiomyocytes of neonatal rat to observe the protective effect of GXN on heart failure rat model and the intervention effect on myocardial cell hypertrophy, and to explore the possible mechanism of GXN preventing and treating myocardial hypertrophy. The results of in vivo experiments showed that GXN could significantly reduce the degree of cardiac hypertrophy, reduce the size of cardiomyocytes, inhibit the degree of myocardial remodeling and fibrosis, and improve cardiac function in rats with early heart failure. The results of in vitro experiments showed that GXN was safe for primary cardiomyocytes and could improve cardiomyocyte hypertrophy and reduce the apoptosis of cardiomyocytes in pathological state, which may be related to the inhibition of the over-activation of MEK-ERK1/2 signaling pathway. In conclusion, GXN may inhibit cardiac hypertrophy and improve early heart failure by inhibiting the over-activation of MEK-ERK1/2 signaling pathway.
Zhang et al. (Mon,) conducted a other in Myocardial hypertrophy and early heart failure (n=47). Guanxinning tablets (GXN) vs. Model control and Captopril (12.5 mg/kg) was evaluated on Ventricular wall thickness and heart coefficient (p=<0.05). Guanxinning tablets significantly reduced cardiac hypertrophy, inhibited myocardial remodeling and fibrosis, and improved cardiac function in rats with early heart failure by inhibiting the MEK-ERK1/2 signaling pathway.